At Rx|X our mission is clear - we relieve the uncertainty and stress surrounding 340B program compliance. Rx|X is committed to maintaining the integrity of the 340B Program, while also ensuring your program implementation makes financial sense. We provide audit services to large 340B entity services, with the majority of our clients being multi-site research-based university hospital systems. Rx|X conducts full program compliance reviews and independent contract pharmacy audits to ensure entities are meeting HRSA requirements and industry best practices. We also offer education and training, dispute resolution and HRSA audit preparation services to pharmaceutical manufacturers. Rx|X provides 340B stakeholders with implementable plans to help ensure program compliance. We also assist with the implementation of 340B and offer strategic insights on program structure or redesign, taking the guesswork out of your path to compliance and efficient implementation. Rx|X founders Dr. Madeline Wallack and Ms. Suzanne Herzog have dedicated their careers to 340B program and policy work. In addition to their academic research and advising, their experience includes: - Senior-level positions with the Office of the Inspector General (OIG) - Serving as 340B subject matter experts for litigation and Apexus - Contracting with HRSA via APhA for entity technical assistance and policy projects At Rx|X we share our years of experience and provide you with the counsel and guidance necessary to execute efficient and compliant programs. Clients find that the key differentiating benefit of working with Rx|X is receiving the full focus of an industry-dedicated team. Offering personable, individual service and attention, in the field and throughout the engagement, Rx|X offers unbiased perspective and credible advice.